Accurexa Inc., of Walnut Creek, Calif., and Stemimmune Inc., of San Diego, inked a collaboration to develop a stem cell-mediated immunotherapy for the treatment of cancers, such as brain cancer. Stemimmune's immunotherapy uses the stealth anticancer payload-carrying and tumor-seeking capacities of a patient's own readily available stem cells to target the disease. Terms were not disclosed.